Canada has become the first country to fully approve Johnson & Johnson's (NYSE:JNJ) single-dose Covid-19 vaccine. According to a statement, regulators based their decision on the Phase 3 ENSEMBLE study, which showed an 85% efficacy against severe disease.

• The move comes after Health Canada granted full approval to the Pfizer Inc (NYSE:PFE) / BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) vaccines in September. 
• The rollout of J&J's vaccine in Canada was slower than expected after it was discovered that the country's first shipment of doses had been processed at the Emergent BioSolutions Inc (NYSE:EBS) plants, according to CBC News. 
• Earlier this month, Health Canada authorized booster doses of the Pfizer and Moderna vaccines but has yet to give a green signal to JNJ's booster shot.
• Also Read: Millions Of JNJ COVID-19 Shots Sit Idle At Emergent's Baltimore Plant: Reuters.
• Price Action: JNJ shares are down 0.09% at $160.54 during the market session on the last check Wednesday.
• Photo by Spencer Davis from Pixabay